Thoracic Malignancies: Insights into Different Therapeutic and Technical Options

Massimo Baudo^1*, Mohamed Rahouma^2*, Faiza Khan, M.³, Dina Ibrahim, A.⁴, Fatma Abou Elkasem⁵, Mohamed Kamel², Ihab Saad², Maha Yehia⁵, Ihab Eldessouki⁶, Irbaz Hameed⁷ & Abdelrahman Mohamed²

¹IRCCS Vita-Salute San Raffaele Hospital Via Olgettina, Italy
²Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt
³Department of Surgery, Louisiana State University Health Sciences Center in New Orleans, USA
⁴Department of Medicine, Brown University, Providence, USA
⁵Medical Oncology Department, National Cancer Institute, Cairo University, Egypt
⁶Medical Oncology Department, University of Cincinnati Cancer Institute, Cincinnati, Ohio, USA
⁷Department of Surgery, Southeast University, Nanjing, China
^*Equally contributed

Dr. Mohamed Rahouma, Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt, <a

Keywords: Thoracic Malignancy; Chemoradiotherapy; Lung Cancer

Abstract

The World Health Organization (WHO) reports that cancer is the second leading cause of death globally [1]. Focusing on thoracic cancers, there are distinct epidemiological pictures. Among all tumors, lung cancer has the highest incidence and mortality when both genders are taken into consideration together. However, differences are present when each gender is observed individually. In males, lung cancer is the number one cause of mortality and the second highest in incidence, while in females, it is the second most common reason for mortality and the third highest in incidence. On the other hand, esophageal cancer ranks sixth for overall mortality and tenth for overall incidence. It has a higher incidence (seventh) and mortality (sixth) in males compared to females (thirteenth and tenth respectively) [2]. Invasive thymoma and thymic carcinomas are rare tumors, consisting of about 1% of all malignancies, and the incidence and mortality rate in males and females is very similar [3].

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).